We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Places Clinical Hold on Allogene Therapeutics’ CAR-T Therapy Clinical Trials
FDA Places Clinical Hold on Allogene Therapeutics’ CAR-T Therapy Clinical Trials
Following a report of a chromosomal abnormality in a patient, the FDA has placed a hold on Allogene Therapeutics’ early-stage chimeric antigen receptor T (CAR-T) therapy clinical trials.